SHAZ Soars 48% as AI Capacity Surges – EPS Revisions Fuel Rally
Shares of SharonAI Holdings (SHAZ) jumped 48.0% from $49.79 to $73.69 after analysts raised its next-year EPS growth estimate to 86.2%. The move was reinforced by Q2 results showing AI factory capacity up to 212MW, a $4.9bn NVIDIA collaboration, and an $8.8bn contracted revenue book. Aurora Cannabis (ACB) and Hertz (HTZ) also posted double-digit gains on EPS estimate revisions.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| SHAZ | Technology | 2026-08-07 | N/A | +48.0% |
| ACB | Healthcare | 2026-08-06 | +16.1pp | +28.2% |
| HTZ | Industrials | 2026-08-10 | N/A | +23.6% |
| MNTN | Technology | 2026-08-05 | N/A | +20.2% |
| NYXH | Healthcare | 2026-08-06 | +7.0pp | +19.9% |
Why did SHAZ stock jump in August 2026?
SHAZ jumped 48.0% (from $49.79 to $73.69) after analysts raised its next-year EPS growth estimate to 86.2% on August 7.
The rally followed Q2 results showing AI factory capacity surged to 212MW (up from 132MW) and a $4.9bn, six-year NVIDIA collaboration for up to 40,000 GB300 GPUs. The company's contracted revenue book reached $8.8bn year-to-date, with demand outpacing supply and pricing above $4 per GPU hour. The earnings call highlighted strong funding from a $2.2bn capital raise, underpinning the positive EPS revision.
SHAZ EPS revision history → · Screener snapshot from 2026-08-07 →
FAQ: SHAZ
Why did SHAZ stock jump in August 2026?
SHAZ jumped 48.0% after its next-year EPS growth estimate was revised upward to 86.2% and Q2 results showed AI capacity surged to 212MW.
Is SHAZ a buy after the rally?
SHAZ's Q2 results and the EPS revision suggest strong growth, but material revenue isn't expected until Q4 2026, making it a higher-risk, higher-reward opportunity.
What is SHAZ's EPS growth estimate?
SHAZ's next-year EPS growth estimate is 86.2%, reflecting expectations of rapid earnings expansion.
Why did ACB stock jump in August 2026?
ACB jumped 28.2% (from $2.98 to $3.82) after analysts raised its next-year EPS growth estimate from 91.5% to 107.5% on August 6.
The revision followed Q1 fiscal 2027 results showing international medical cannabis revenue rose 17% to CAD43 million, with 64% of total revenue now from outside Canada. Adjusted gross margin hit 58%, at the high end of guidance, and the company boasts nearly CAD150 million in cash with no debt. The August 10 annual meeting passed key resolutions, including say-on-pay, reflecting shareholder confidence.
ACB EPS revision history → · Screener snapshot from 2026-08-06 →
FAQ: ACB
Why did ACB stock jump recently?
ACB rose 28.2% as its EPS growth estimate was revised up to 107.5%, following strong international cannabis revenue growth and a clean balance sheet.
What is ACB's EPS growth estimate?
ACB's next-year EPS growth estimate is 107.5%, up from 91.5% earlier.
What caused ACB's surge in August 2026?
ACB's Q1 results showing 17% international revenue growth, 58% gross margin, and zero debt, combined with a positive EPS revision, fueled the surge.
Why did HTZ stock jump in August 2026?
HTZ jumped 23.6% (from $2.12 to $2.62) after analysts raised its next-year EPS growth estimate to 88.4% on August 10, with no major earnings news in the window.
The move likely reflects the market's growing confidence in a cyclical recovery in car rental demand and cost discipline, driving the upward revision. The screener detected the revision early, and the subsequent price gain confirms the market's recognition of improved earnings prospects.
HTZ EPS revision history → · Screener snapshot from 2026-08-10 →
FAQ: HTZ
Why did HTZ stock jump in August 2026?
HTZ jumped 23.6% after its next-year EPS growth estimate was revised up to 88.4%, signaling expected earnings recovery.
Is HTZ a buy after the rally?
The positive EPS revision suggests improving profitability, but investors should watch for continued confirmation in upcoming earnings.
What is HTZ's EPS growth estimate?
HTZ's next-year EPS growth estimate is 88.4%, indicating strong expected earnings growth.
Why did MNTN stock jump in August 2026?
MNTN jumped 20.2% (from $10.43 to $12.54) after analysts raised its next-year EPS growth estimate to 35.7% on August 5.
The revision followed Q2 revenue of $82.5 million (up 21% year-over-year) and adjusted EBITDA of $21.5 million (up 48%). Management raised Q3 revenue guidance to $86–$89 million, and a $100 million buyback authorized on August 3 added support. The company's expansion into 'super premium' content and platform restructuring signal broad demand for connected TV advertising.
MNTN EPS revision history → · Screener snapshot from 2026-08-05 →
FAQ: MNTN
Why did MNTN stock jump?
MNTN rose 20.2% after its EPS estimate was revised up to 35.7%, driven by Q2 results that beat expectations and raised guidance.
Is MNTN a buy after the rally?
MNTN's growth metrics (revenue up 21%, adjusted EBITDA up 48%) and strong cash position make it attractive, but the 35.7% EPS growth estimate is moderate.
What is MNTN's EPS growth estimate?
MNTN's next-year EPS growth estimate is 35.7%, reflecting continued profitability improvement.
Why did NYXH stock jump in August 2026?
NYXH jumped 19.9% (from $1.31 to $1.57) after analysts raised its next-year EPS growth estimate from 27.8% to 34.8% on August 6.
The revision followed Q2 results showing US revenue up 22% sequentially to EUR5.2 million and a doubling of active accounts to 180. A $110 million financing removed near-term balance sheet overhang, and proposed CMS reimbursement increases of up to 15% for the Genio procedure provide a tailwind. International revenue grew 19% sequentially, with Germany reaching break-even.
NYXH EPS revision history → · Screener snapshot from 2026-08-06 →
FAQ: NYXH
Why did NYXH stock jump?
NYXH gained 19.9% as its EPS growth estimate was revised up to 34.8%, following strong US revenue growth and a $110 million financing.
What caused NYXH's surge?
The surge was driven by a 22% sequential rise in US revenue, active accounts doubling, and proposed reimbursement increases.
What is NYXH's EPS growth estimate?
NYXH's next-year EPS growth estimate is 34.8%, up from 27.8%.
Today's top performers underscore the market's appetite for companies with strong earnings revisions and clear catalysts – from AI infrastructure (SHAZ) to medical cannabis (ACB) and connected TV (MNTN). Positive estimate revisions are being quickly rewarded, suggesting a sentiment shift toward growth names with improving fundamentals.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →